文献速递前列腺癌

局限性前列腺癌管理全球基准质量指标的开发

Quality Indicators for Global Benchmarking of Localized Prostate Cancer Management.
PubMed 文献 · J Urol · 2018-03-01

国际专家小组通过改良德尔菲法开发了一套用于局限性前列腺癌管理国际基准比较的核心临床指标。这些指标将在TrueNTH全球注册中进行试点测试,以改善全球前列腺癌管理的一致性和质量。

要点

  • 专家小组认可33项局限性前列腺癌质量指标,涵盖诊断、治疗和健康结局。
  • 指标基于重要性(中位≥8.5)和可行性(中位≥9)标准, disagreement index<1。
  • 指标将在TrueNTH全球注册中试点测试,用于国际基准比较。

核心结论

  • 开发了一套基于国际循证指南的局限性前列腺癌质量指标,用于全球基准比较。

研究设计与样本

  • 通过在线调查和面对面会议,采用改良德尔菲法对潜在质量指标进行重要性(满足指标表明提供高质量护理)和可行性(构建指标的数据可在人群水平收集的可能性)评级。

主要发现

  • 专家小组共认可33项前列腺癌质量指标。
  • 33项指标中,7项评估诊断相关护理,7项评估主要治疗,1项评估挽救治疗,18项评估健康结局。

关键数值与推荐

  • 指标入选标准为:小组一致同意(disagreement index<1)、重要性中位数≥8.5、可行性中位数≥9。

临床怎么用

  • 这些指标将在TrueNTH全球注册中进行试点测试,随后将指标性能比较报告分发给参与站点,以改善全球前列腺癌管理的一致性和质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to develop a core set of clinical indicators to enable international benchmarking of localized prostate cancer management using data available in the TrueNTH Global Registry. MATERIALS AND METHODS: An international expert panel completed an online survey and participated in a face-to-face meeting. Participants included 3 urologists, 3 radiation oncologists, 2 psychologists, 1 medical oncologist, 1 nurse and 1 epidemiologist with prostate cancer expertise from a total of 7 countries. Current guidelines on prostate cancer treatment and potential quality indicators were identified from a literature review. These potential indicators were refined and developed through a modified Delphi process during which each panelist independently and repeatedly rated each indicator based on importance (satisfying the indicator demonstrated a provision of high quality care) and feasibility (the likelihood that data used to construct the indicator could be collected at a population level). The main outcome measure was items with panel agreement indicated by a disagreement index less 1, median importance 8.5 or greater and median feasibility 9 or greater. RESULTS: The expert panel endorsed 33 indicators. Seven of these 33 prostate cancer quality indicators assessed care relating to diagnosis, 7 assessed primary treatment, 1 assessed salvage treatment and 18 assessed health outcomes. CONCLUSIONS: We developed a set of quality indicators to measure prostate cancer care using numerous international evidence-based clinical guidelines. These indicators will be pilot tested in the TrueNTH Global Registry. Reports comparing indicator performance will subsequently be distributed to groups at participating sites with the purpose of improving the consistency and quality of prostate cancer management on a global basis.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Sampurno F, Zheng J, Di Stefano L, et al. Quality Indicators for Global Benchmarking of Localized Prostate Cancer Management. J Urol. 2018. PMID: 29477721. doi:10.1016/j.juro.2018.02.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。